November 29, 2021 - 1,000 subjects enrolled in RESUME-1
November 24, 2021 - Presentation at Piper Sandler 33rd Annual Healthcare Conference
September 2, 2020 - Phase 2 STAR Study Encore Poster and Phase 3 Overview
July 7, 2021 - Neurana Pharmaceuticals Announces Publication in Pain Management
June 25, 2021 - Presentation of CNS Effects Study at ASIPP
June 7, 2021 - 50% of subjects enrolled in RESUME-1
June 1, 2021 - Georgia Erbez and Liz Cermak to join BOD
May 11, 2021 - Presentation at Pain Therapeutics Conference
December 21, 2020 - First patient enrolled in RESUME-1
December 8, 2020 - Positive top-line results from Phase 1 CNS Effects Study
November 24, 2020 - Presentation at Piper Sandler 32nd Annual Healthcare Conference
November 23, 2020 - Publication in the Journal of Pain Research
July 30, 2020 - Neurana to present at LifeSci Partners Summer Symposium on August 5th
August 4, 2020 - Neurana to present at Solebury Trout Private Company Showcase on August 10th
June 8, 2020 - First patient has been enrolled in the Phase 1 central nervous effects (CNS) clinical study of tolperisone
May 12, 2020 - Publication of a driving study demonstrating the effects of tolperisone
February 26. 2020 - Neurana Pharmaceuticals to participate in Cowen Health Care Conference
November 7, 2019 - Randall Kaye, M.D., appointed as Chief Medical Officer
October 14, 2019 - Neurana Pharmaceuticals to participate in Solebury Trout Private Company Showcase
September 23, 2019 - Positive topline results from Phase 2 STAR Study of tolperisone in acute muscle spasms of the back
June 17, 2019 - Completed enrollment in Phase 2 STAR Study of tolperisone in over 400 patients
February 4, 2019 - First patient enrolled in Phase 2 dose ranging study of tolperisone
October 17, 2018 - Presentation will highlight data demonstrating the non-sedating effects of tolperisone
October 17, 2018 - Presentation will highlight data demonstrating the non-sedating effects of tolperisone
July 17, 2018 - Craig brings over 25 years of executive, commercial and marketing experience to Neurana
May 7, 2018 - Funding to advance tolperisone led by Sofinnova Ventures
October 26, 2017 - Non-sedative effects of tolperisone confirmed in Phase 1 study
October 26, 2017 - Study to assess non-sedating properties of tolperisone initiated
May 25, 2017 - Notice of Allowance patents received for two, new tolperisone patents